Project Grant R01CA293587
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $3.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $434,361.00 to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a multispecific T cell engaging therapy for the treatment of mixed phenotype acute leukemia (MPAL). MPAL is a high-risk leukemia subtype that presents with both myeloid (e.g. CD33) and lymphoid (e.g. CD19) surface antigens, resulting in lower cure rates compared to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The $470,759 award, commencing on September 1, 2025, aims to prevent CAR T-cell exhaustion and improve the antitumor activity of GPC3-CAR T-cells through the precise, on-demand control...
- The federal Project Grant award titled "Investigating and Targeting NSD2 Mutation-Driven Leukemia Transformation" is funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) in the amount of $484,405.00 with a performance period from September 1, 2025 to August 31, 2030. The grant was awarded to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, a private non-profit academic medical center in Pennsylvania. The project aims to...
- The Department of Defense's Defense Health Agency awarded a $3,188,604 Project Grant titled "USE OF HIGH-THROUGHPUT SEQUENCING OF THE IMMUNOGLOBULIN LOCI FOR REFINED RISK STRATIFICATION IN PEDIATRIC B-ALL" to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. This grant, funded through the Military Medical Research and Development (CFDA 12.420) program, supports biomedical research related to military medicine, with a focus on cancer, neurological...
- The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $530,106 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, awarded on September 11, 2025, supports research aimed at understanding and targeting polyamine metabolism in leukemia stem cells (LSCs) to improve outcomes for patients with acute myeloid leukemia (AML). The overarching goal is to develop LSC-directed therapies that can help overcome...
- This Project Grant award of $434,993 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Children's Hospital Los Angeles. The funding supports research using high-throughput sequencing of the immunoglobulin loci to develop refined risk stratification methods for pediatric B-cell acute lymphoblastic leukemia (B-ALL). The project aims to advance understanding and treatment of this pediatric cancer, with an expected completion...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to St. Jude Children's Research Hospital Inc. for $768,713 on August 1, 2025. The funding supports research to dissect how the EP300 and CBP histone acetyltransferase proteins control cell state-specific phenotypes and chemosensitivity in high-risk neuroblastoma. The objectives are to capitalize on transcriptional control to identify mechanism-based, targeted cancer therapies that can...
- This $517,090 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope supports innovative research aimed at understanding the role and function of a novel gene, A978, which is overexpressed in Philadelphia chromosome-positive and Philadelphia-like B-cell acute lymphoblastic leukemia (B-ALL). The key objectives of this 5-year project are to: 1) determine the biological effects of A978 in...
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...
- The National Cancer Institute (NCI) awarded a $177,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The funding supports research to investigate the role of the NLRC4 inflammasome and caspase-8 activation in the pathogenesis of fibrolamellar carcinoma (FLC), a rare and aggressive form of liver cancer. The researchers will use mouse liver organoids engineered with the DNAJB1-PRKACA...